Novartis Q3 core EPS $2.46 vs $2.28 estimate

The beat is driven by margin rather than volume: core operating profit and net income cleared estimates by wider gaps than sales, which edged past forecasts only narrowly. That distinction matters because it suggests cost leverage or mix, not demand acceleration, is doing the work — and the two named products, Cosentyx and Entresto, are the franchises most exposed to pricing and competition scrutiny. For RWA and tokenization watchers, this is a reminder that large-cap pharma earnings remain a conventional benchmark, not an on-chain signal. Whether the profit beat reflects durable operating discipline or a one-quarter cost effect is the open question.